Dana-Farber study of genomic testing links ‘exceptional’ drug response to rare mutations in bladder cancer

Dana-Farber study of genomic testing links ‘exceptional’ drug response to rare mutations in bladder cancer A patient with advanced bladder cancer, who was part of a phase 1 clinical trial, had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute … Continue reading “Dana-Farber study of genomic testing links ‘exceptional’ drug response to rare mutations in bladder cancer”

Dana-Farber study of genomic testing links ‘exceptional’ drug response to rare mutations in bladder cancer

A patient with advanced bladder cancer, who was part of a phase 1 clinical trial, had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, and genomic profiling of his tumor revealed two alterations that may have led to this exceptional response.

Click here to read the full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply